Sana reports Q3 2026 progress on SC451 and SG293, NEJM data on UP421

Sana Biotechnology reported third quarter 2026 results on November 5, 2026, highlighting progress across its pipeline of engineered cell therapies. The company said it is advancing toward dosing patients in two new clinical programs. Sana expects to file an investigational new drug application and begin a Phase 1/2 clinical trial for SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes, as early as this year.¹ CEO Steve Harr said the company is also working toward starting a study of SG293, a CD8-targeted fusosome for non-Hodgkin lymphoma, with plans to initiate that trial in the first quarter of 2027.¹

On the preclinical side, Sana is preparing to begin clinical testing of SG227, a BCMA-directed CAR T candidate for multiple myeloma, as early as 2027, contingent upon the early clinical profile of SG293.¹

The company also reported longer-term data from an investigator-sponsored study of UP421, an islet cell therapy given without immunosuppression. Results through 14 months after transplantation showed survival and function of pancreatic beta cells as measured by circulating C-peptide, with levels rising during mixed meal tolerance tests consistent with insulin secretion in response to a meal.¹ The study identified no safety issues, and the HIP-modified cells evaded immune detection.¹ These findings were also published as a Letter to the Editor in The New England Journal of Medicine titled "Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression."¹

Sana said it is expanding a collaboration with Mayo Clinic aimed at accelerating development, validation, and standardization of protocols for SC451 to support delivery across diverse clinical settings.¹

On finances, cash, cash equivalents, and marketable securities were $121.7 million as of September 30, 2026, compared with $138.4 million at the end of 2025.¹ The company said it expects its cash runway to extend into mid-2027.